The Ambulatory Medical Assistance (AMA) programme during active-phase treatment in patients with haematological malignancies: A cost-effectiveness analysis.

The need for patient navigator is growing, and there is a lack of cost evaluation, especially during survivorship. The objective of this study is to evaluate the cost-effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies (HM). A cost-effectiveness analysis of the AMA programme was performed compared to a simulated control arm. An interventional, single-arm and prospective study was conducted in a French reference haematology-oncology centre between 2016 and 2020. Adult patients were enrolled with histologically documented malignant haematology, during their active therapy phase, and treated either by intravenous chemotherapy or oral therapy. An extrapolation of the effectiveness was derived from a similar nurse monitoring programme (CAPRI study). Cost effectiveness of the programme was evaluated through adverse events of Grade 3 or 4 avoided in different populations. Included patient (n = 797) from the AMA programme were followed during 125 days (IQR: 0-181), and adverse events (Grade 3/4) were observed in 10.1% of patients versus 13.4% in the simulated control arm. The overall cost of AE avoided was estimated to €81,113, leading to an ICER of €864. The AMA programme was shown to be cost-effective compared to a simulated control arm with no intervention.

Informations de copyright

© 2022 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd.